Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 349

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 7
Chunk 349
---
 Securities and Exchange Commission, or the SEC; and investor and public relations costs.

Gain from sale of priority review voucher

Gain from the sale of priority review voucher represents the sale of our rare pediatric disease PRV, which was awarded to us in connection with the FDA’s approval of OJEMDA.

118

Results of operations

Comparison of year ended December 31, 2024 and 2023 

The following table summarizes our results of operations for the years ended December 31, 2024 and 2023:

    Year EndedDecember 31,

    2024

    2023

    $ Change

    % Change

    Revenue:

    Product revenue, net
     
    $
    57,217

    $
    —

    $
    57,217

    *

    License revenue

    73,944

    —

    73,944

    *

    Total revenues

    131,161

    —

    131,161

    *

    Cost and operating expenses:

    Cost of product revenue

    5,279

    —

    5,279

    *

    Research and development

    227,702

    130,521

    97,181

    74.5
    %

    Selling, general and administrative

    115,450

    75,543

    39,907

    52.8
    %

    Total cost and operating expenses

    348,431

    206,064

    142,367

    69.1
    %

    Loss from operations

    (217,270
    )

    (206,064
    )

    (11,206
    )

    5.4
    %

    Non-operating income (expense):

    Gain from sale of priority review voucher

    108,000

    —

    108,000

    *

    Investment income, net

    19,701

    17,187

    2,514

    14.6
    %

    Other income (expense), net

    1,217

    (40
    )

    1,257

    *

    Total non-operating income, net

    128,918

    17,147

    111,771

    *

    Loss before income taxes

    (88,352
    )

    (188,917
    )